Phase III
The goal of the trial was to evaluate the efficacy and safety of the drug in patients six years of age and older with SCD who were hospitalized for a vaso-occlusive crisis and required treatments with intravenous opioids.
Every week brings news of clinical trials, ranging from launches, first-patient dosing, full enrollment, interim data or final data. Here’s a look at some of the clinical trial news from last week.
AZTherapies, Inc. announced that it has completed target enrollment in its COGNITE Phase 3 clinical trial, evaluating the safety and efficacy of ALZT-OP1 for the treatment of early Alzheimer’s disease.
Novartis announced that its Phase III MONALEESA-3 clinical trial of Kisqali (ribociclib) hit its key secondary endpoint, overall survival, in a pre-planned interim analysis.
Atlantic Healthcare plc, a specialist pharmaceutical company focused on acquiring, developing and commercializing therapeutics that address unmet patient needs and rare diseases, announced the results of the Phase 3 trial of Camligo™ for orphan-designated pouchitis.
Daiichi Sankyo Europe GmbH announced that results from the 12-week, pivotal Phase 3 bempedoic acid / ezetimibe FDC tablet study (also known as Study 053) were published in the European Journal of Preventative Cardiology.
Biogen and Alkermes announced positive topline data from EVOLVE-MS-2, a Phase III trial of diroximel fumarate for relapsing-remitting multiple sclerosis compared to Tecfidera.
The DMC recommended the trial continue without changes in order to determine other dual-primary endpoints, such as event-free survival.
We embarked upon the landmark Phase III PARAGON-HF trial to determine whether sacubitril/valsartan could have a meaningful impact on the treatment of HFpEF, as it does in the treatment of heart failure with reduced ejection fraction,” stated John McMurray, professor of Medical Cardiology at University of Glasgow and PARAGON-HF Executive Committee Co-Chair.
A number of companies reported clinical trial data last week. Here’s a look.
PRESS RELEASES